The Medicines Company (NASDAQ:MDCO) Analyst Ratings as of May 17, 2018

May 17, 2018 - By Robert Shackelford

The Medicines Company (NASDAQ:MDCO) Corporate Logo
Big Money Sentiment increased to 1.25 in 2017 Q4. It has change of 0.47, from 2017Q3’s 0.78. The ratio increased due to The Medicines Company positioning: 26 sold and 51 reduced. 28 funds bought positions and 68 increased positions. Investors holded 85.15 million in 2017Q3 but now own 89.44 million shares or 5.03% more.
683 Capital Management Ltd Liability has 0.12% invested in The Medicines Company (NASDAQ:MDCO). Pinebridge Limited Partnership, a New York-based fund reported 78,548 shs. Hall Laurie J Trustee invested 0.01% of its capital in The Medicines Company (NASDAQ:MDCO). Comerica Natl Bank reported 66,376 shs. Citadel Advsr Limited Com owns 359,731 shs. Metropolitan Life Ins Com Ny reported 22,118 shs or 0.01% of all its holdings. Glenmede Trust Na accumulated 357 shs. 60,000 are owned by Iguana Healthcare Management Ltd Com. Royal Bancorporation Of Canada holds 0% of its capital in The Medicines Company (NASDAQ:MDCO) for 1,344 shs. Whittier Trust Of Nevada holds 1,359 shs or 0% of its capital. Westfield Cap Com Limited Partnership reported 0.61% of its capital in The Medicines Company (NASDAQ:MDCO). Guggenheim Capital Ltd reported 100,424 shs. Stevens Capital Management L P invested in 0.01% or 9,122 shs. Ameriprise Financial Inc holds 0.01% or 472,955 shs in its capital. Gp One Trading Lp owns 67,829 shs or 0.01% of their US capital.

The Medicines Company registered $783,400 net activity with 1 buy and 3 selling transactions since December 7, 2017. On Thursday, December 7 ESHELMAN FREDRIC N bought $5.31M worth of The Medicines Company (NASDAQ:MDCO). On Wednesday, March 21 7,500 shs were sold by CROUSE WILLIAM, worth $241,950. Another trade for 136,250 shs valued at $3.71 million was sold by MEANWELL CLIVE.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

A total of 3 analysts rate Medicines Co (NASDAQ:MDCO) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:MDCO) has 6 ratings reports on May 17, 2018 according to StockzIntelligence. On Thursday, February 22 the stock of The Medicines Company (NASDAQ:MDCO) earned “Hold” rating by Oppenheimer. On Monday, January 15 the rating was maintained by Oppenheimer with “Buy”. On Thursday, March 22 the stock of The Medicines Company (NASDAQ:MDCO) earned “Buy” rating by Oppenheimer. On Monday, January 22 the rating was upgraded by Citigroup to “Buy”. On Wednesday, November 29 Oppenheimer upgraded the shares of MDCO in report to “Buy” rating. Listed here are The Medicines Company (NASDAQ:MDCO) PTs and latest ratings.

22/03/2018 Broker: Oppenheimer Rating: Buy Maintain
22/02/2018 Broker: Oppenheimer Rating: Hold New Target: $50.0 Maintain
24/01/2018 Broker: J.P. Morgan Rating: Buy New Target: $45.0
22/01/2018 Broker: Citigroup Rating: Buy New Target: $40.0 Upgrade
15/01/2018 Broker: Oppenheimer Rating: Buy New Target: $50.0 Maintain
29/11/2017 Broker: Oppenheimer Rating: Buy New Target: $50.0 Upgrade

Ticker’s shares touched $32.2 during the last trading session after 0.22% change.Currently The Medicines Company is downtrending after 34.73% change in last May 17, 2017. MDCO has 288,319 shares volume. MDCO underperformed by 46.28% the S&P500.

The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide.The firm is worth $2.37 billion. The firm markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital.Currently it has negative earnings. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms.

For more The Medicines Company (NASDAQ:MDCO) news brought out recently go to: Streetinsider.com, Streetinsider.com, Fool.com, Seekingalpha.com or Fool.com. The titles are as follows: “Einhorn’s Greenlight Capital Enters Office Depot (ODP), Abercrombie & Fitch (ANF) (more…) – 13F” brought out on May 15, 2018, “Medicines Co. (MDCO) ORION-1 Phase II Study Shows Significant Reductions in Potentially Harmful Subtypes of Bad …” on May 07, 2018, “Alnylam Looks Forward” with a publish date: May 08, 2018, “The Medicines (MDCO) Q1 2018 Results – Earnings Call Transcript” and the last “Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?” with publication date: May 17, 2018.

The Medicines Company (NASDAQ:MDCO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.